- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Four Pillars of Heart Failure Therapy
Therapy strategies in the management of heart failure are discussed.
EP: 1.Identifying Key Risk Factors for Heart Failure
EP: 2.Socioeconomic Factors Impacting Development of Cardiac Disease
EP: 3.Distinguishing Between Heart Failure Classifications
EP: 4.Staging Heart Failure and the Importance of Early Diagnosis
EP: 5.The Role of the Primary Care Physician in Heart Failure Management
EP: 6.Four Pillars of Heart Failure Therapy
EP: 7.Selecting Optimal First-line Therapy for Patients Diagnosed with Heart Failure
EP: 8.Key Takeaways From Heart Failure Clinical Trials
EP: 9.Navigating the Patient Journey Through Heart Failure Diagnosis
EP: 10.Strategies for Treating Preserved Ejection Fraction (HFpEF)
EP: 11.Treatment Optimization Challenges Associated With Heart Failure
EP: 12.Financial Barriers Impeding Optimal Heart Failure Treatment
EP: 13.Trajectory of Heart Failure Treatment Strategies
EP: 14.Key Takeaways from Experts in Heart Failure Management
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. Axsom, MD, outlines the 4 pillars of guideline-directed medical therapy for symptomatic heart failure with reduced ejection fraction (HFrEF), which also applies to midrange ejection fraction (EF): angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs); evidence-based beta blockers (metoprolol succinate, bisoprolol, carvedilol); mineralocorticoid receptor antagonists (MRAs; spironolactone, eplerenone); and sodium-glucose cotransporter-2 (SGLT2) inhibitors (dapagliflozin, empagliflozin). The specific beta blockers reduce 1-year mortality by 36% based on randomized controlled trial data. For heart failure with preserved ejection fraction (HFpEF), treatment focuses on managing comorbidities until EF declines below 60% to 65%. Implementation and adherence to guideline-directed medical therapy remains a challenge. The classification system helps guide evidence-based treatments for HFrEF, while HFpEF management is more limited but evolving.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
